Genetic Characteristics of Cutaneous, Acral, and Mucosal Melanoma in Japan

被引:1
|
作者
Hida, Tokimasa [1 ]
Idogawa, Masashi [2 ]
Kato, Junji [1 ]
Kiniwa, Yukiko [3 ]
Horimoto, Kohei [1 ]
Sato, Sayuri [1 ]
Sawada, Masahide [1 ]
Tange, Shoichiro [2 ]
Okura, Masae [1 ]
Okuyama, Ryuhei [3 ]
Tokino, Takashi [2 ]
Uhara, Hisashi [1 ]
机构
[1] Sapporo Med Univ, Sch Med, Dept Dermatol, Sapporo, Japan
[2] Sapporo Med Univ, Canc Res Inst, Sch Med, Dept Med Genome Sci, Sapporo, Japan
[3] Shinshu Univ, Sch Med, Dept Dermatol, Nagano, Japan
来源
CANCER MEDICINE | 2024年 / 13卷 / 22期
基金
日本学术振兴会;
关键词
DNA copy number variation; immune checkpoint inhibitor; melanoma; molecular targeted therapy; mutation; BRAF; DACARBAZINE; IPILIMUMAB; INHIBITORS; SURVIVAL; CANCER; NRAS;
D O I
10.1002/cam4.70360
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
BackgroundAcral and mucosal melanomas are more prevalent in Asians than in Caucasians, unlike cutaneous melanomas, which are predominant in Caucasians. Recent studies have suggested that non-Caucasian cutaneous melanomas responded less to immune checkpoint inhibitors, highlighting the need for genetic profiling across ethnicities. This study aimed to elucidate the genetic characteristics of Japanese melanomas, which is an under-researched topic.MethodsSingle-nucleotide variants, indels, and copy number alterations in 104 Japanese melanoma patients (37 cutaneous, 52 acral, and 15 mucosal) were analyzed using custom panel sequencing.ResultsDriver events were detected in 94% of the cases. Among cutaneous melanoma cases, 76% had BRAF mutations, and 8% had NRAS mutations. In acral melanoma, BRAF (9%), NRAS (17%), KRAS (8%), KIT (19%), and NF1 (7%) mutations were detected. Major driver mutations in mucosal melanoma were detected in NRAS, KRAS, NF1, PTEN, GNAQ, and KIT. The median tumor mutational burden across all melanoma types was 4.6 mutations/Mb, with no significant difference between the cutaneous and acral/mucosal types. Of the 21 patients with both primary and metastatic lesions, 11 showed distinct mutations in each. Potentially actionable mutations were detected in 58 patients in addition to BRAF V600E/K mutations in 31.ConclusionsThis study highlights distinct genetic abnormalities and actionable alterations in Japanese melanoma patients. This suggests a lower tumor mutational burden in East Asian cutaneous melanoma, which may affect the efficacy of immune checkpoint inhibitors. The heterogeneity of driver mutations across and within individuals highlights the need for personalized treatment approaches.
引用
收藏
页数:12
相关论文
共 50 条
  • [41] Cutaneous involvement in multiple myeloma mimicking acral-lentiginous melanoma
    Martorell, Antonio
    Millan-Parrilla, Fernando
    Gimeno-Carpio, Enrique
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2010, 62 (06) : 1076 - 1078
  • [42] Subtype-dependent differences in genomic profiles of acral and cutaneous melanoma
    Kim, D. Y.
    Buchbinder, E. I.
    Hartman, R.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2022, 142 (08) : S16 - S16
  • [43] GENETIC PREDISPOSITION IN CUTANEOUS MELANOMA
    Aviles, Jose A.
    Lazaro, Pablo
    ACTAS DERMO-SIFILIOGRAFICAS, 2006, 97 (04): : 229 - +
  • [44] National Comprehensive Analysis of Characteristics of Acral Lentiginous Melanoma
    Huayllani, Maria T.
    Restrepo, David J.
    Boczar, Daniel
    Avila, Francisco R.
    Bagaria, Sanjay P.
    Spaulding, Aaron C.
    Rinker, Brian D.
    Forte, Antonio J.
    ANTICANCER RESEARCH, 2020, 40 (06) : 3411 - 3415
  • [45] COLONIZATION OF NONMELANOCYTIC CUTANEOUS LESIONS BY DENDRITIC MELANOCYTIC CELLS - A SIMULANT OF ACRAL-LENTIGINOUS (PALMAR-PLANTAR-SUBUNGUAL-MUCOSAL) MELANOMA
    LAMBERT, MW
    LAMBERT, WC
    SCHWARTZ, RA
    MESA, ML
    BRODKIN, RH
    ABBEY, AH
    POTTER, GK
    LITTLE, WP
    JOURNAL OF SURGICAL ONCOLOGY, 1985, 28 (01) : 12 - 18
  • [46] Acral melanoma
    Persechino, Flavia
    Longo, Caterina
    Benati, Elisa
    Borsari, Stefania
    Lombardi, Mara
    Piana, Simonetta
    Argenziano, Giuseppe
    Moscarella, Elvira
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2017, 76 (02) : S34 - S36
  • [47] Epigenetics Markers in Acral Lentiginous/Mucosal Melanoma: Expression of EZH2
    Li-Ning-Tapia, E. M.
    Curry, J.
    Zhang, P.
    Prieto, V. G.
    Torres-Cabala, C. A.
    LABORATORY INVESTIGATION, 2011, 91 : 119A - 120A
  • [48] Immune checkpoint inhibitor-based therapy for advanced acral and mucosal melanoma
    Mori, Tatsuhiko
    Izumi, Teruaki
    Doi, Reiichi
    Kamimura, Anna
    Takai, Sayaka
    Teramoto, Yukiko
    Nakamura, Yasuhiro
    EXPERIMENTAL DERMATOLOGY, 2023, 32 (03) : 276 - 289
  • [49] Epigenetics Markers in Acral Lentiginous/Mucosal Melanoma: Expression of EZH2
    Li-Ning-Tapia, E. M.
    Curry, J.
    Zhang, P.
    Prieto, V. G.
    Torres-Cabala, C. A.
    MODERN PATHOLOGY, 2011, 24 : 119A - 120A
  • [50] Efficacy and tolerability of vemurafenib in BRAF-mutant acral and mucosal melanoma.
    Bai, Xue
    Si, Lu
    Chi, Zhihong
    Sheng, Xinan
    Cui, Chuanliang
    Kong, Yan
    Dai, Jie
    Mao, Li Li
    Wang, Xuan
    Li, Si Ming
    Tang, Bixia
    Lian, Bin
    Zhou, Li
    Yan, Xieqiao
    Guo, Jun
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35